1. 1) Winyard PG. Chapter 1: Key stages in the acute inflammatory response and their relevance as therapeutic targets. Inflammation protocols. Methods in molecular biology. (Winyard PG, Willoughby DA eds.) Vol. 225, Humana Press, Totowa, pp. 3–6 (2003), https://doi.org/10.1385/1-59259-374-7:3.
2. 2) Grosser T, Smyth E, FitzGerald GA. Chapter 34: Anti-inflammatory, antipyretic, and analgesic agents; pharmacotherapy of gout. The Pharmacological basis of therapeutics 12/e. (Brunton LL, Chabner BA, Knollmann BC eds.), McGraw-Hill, New York, pp. 959–1004 (2011).
3. 3) Kato R, Yamashita S, Moriguchi J, Nakagawa M, Tsukura Y, Uchida K, Amano F, Hirotani Y, Ijiri Y, Tanaka K. Changes of midazolam pharmacokinetics in Wistar rats treated with lipopolysaccharide: relationship between total CYP and CYP3A2. Innate Immun., 14, 291–297 (2008).
4. 4) Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, Richardson TA, Sharma R, Sinal CJ. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab. Dispos., 36, 205–216 (2008).
5. 5) Kajikawa N, Doi M, Kusaba J-I, Aiba T. Effect of carrageenan-induced acute peripheral inflammation on the pharmacokinetics and hepatic metabolism of midazolam in rats. Drug Metab. Pharmacokinet., 29, 400–406 (2014).